Steven Deeks, MD
Co-Director, Clinical Core
Professor, School of Medicine
Email: sdeeks@php.ucsf.edu
Biography
Steven G. Deeks, MD, is a Professor of Medicine in Residence at the University of California, San Francisco (UCSF) and a faculty member in the Division of HIV, Infectious Diseases and Global Medicine at Zuckerberg San Francisco General Hospital. He is an internationally recognized expert on HIV pathogenesis and treatment. He is also now leading a large program focused on the pathogenesis and treatment of Long COVID.
Dr. Deeks has published over 650 peer-review articles, editorials and invited reviews on these and related topics. He has been the recipient of several NIH grants and is the contact principal investigator of DARE (the Delaney AIDS Research Enterprise), an NIH-funded international collaboration aimed at developing therapeutic interventions to cure HIV infection. He recently directed the amfAR Institute for HIV Cure Research. In early 2020, he leveraged his HIV research program to construct the “Long-term Impact of Infection with Novel Coronavirus (LIINC)” cohort, which is now supporting dozens of studies addressing the impact of SARS-CoV-2 on health.
Dr. Deeks is a member of the American Society for Clinical Investigation (ASCI) and Association of American Physicians (AAP). He serves on the scientific advisory board for Science Translational Medicine and is the editor-in-chief of Current Opinion in HIV and AIDS. Based on a recent study conducted at Stanford, he is among the top 0.01% of all scientists, based on citations, adjusted for authorship position and impact, and has been listed by Clarivite as one of the world's most cited scientists for the past several years. In 2022, he received the Lifetime Achievement in Mentoring Award from UCSF.
In addition to his translational and clinical. investigation, Dr. Deeks maintains a primary care clinic for people living with HIV.
Displaying 326 - 350 of 668
- Asher AK, Santos GM, Evans J, Dokubo EK, Lee TH, Martin JN, Deeks SG, Tobler LH, Busch M, Hunt PW, Page K. A closer look at hepatitis C clearance in HIV controllers: a response. AIDS. 2014 May 15; 28(8):1241-2.
- Serrano-Villar S, Sainz T, Lee SA, Hunt PW, Sinclair E, Shacklett BL, Ferre AL, Hayes TL, Somsouk M, Hsue PY, Van Natta ML, Meinert CL, Lederman MM, Hatano H, Jain V, Huang Y, Hecht FM, Martin JN, McCune JM, Moreno S, Deeks SG. HIV-infected individuals with low CD4/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality. PLoS Pathog. 2014 May; 10(5):e1004078.http://www.ncbi.nlm.nih.gov/pubmed/21502083
- Tenorio AR, Zheng Y, Bosch RJ, Krishnan S, Rodriguez B, Hunt PW, Plants J, Seth A, Wilson CC, Deeks SG, Lederman MM, Landay AL. Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment. J Infect Dis. 2014 Oct 15; 210(8):1248-59.
- Symons J, Vandekerckhove L, Hütter G, Wensing AM, van Ham PM, Deeks SG, Nijhuis M. Dependence on the CCR5 coreceptor for viral replication explains the lack of rebound of CXCR4-predicted HIV variants in the Berlin patient. Clin Infect Dis. 2014 Aug 15; 59(4):596-600.
- Hunt PW, Sinclair E, Rodriguez B, Shive C, Clagett B, Funderburg N, Robinson J, Huang Y, Epling L, Martin JN, Deeks SG, Meinert CL, Van Natta ML, Jabs DA, Lederman MM. Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection. J Infect Dis. 2014 Oct 15; 210(8):1228-38.http://www.ncbi.nlm.nih.gov/pubmed/21569420
- Gopal S, Patel MR, Achenbach CJ, Yanik EL, Cole SR, Napravnik S, Burkholder GA, Mathews WC, Rodriguez B, Deeks SG, Mayer KH, Moore RD, Kitahata MM, Richards KL, Eron JJ. Lymphoma immune reconstitution inflammatory syndrome in the center for AIDS research network of integrated clinical systems cohort. Clin Infect Dis. 2014 Jul 15; 59(2):279-86.
- Siewe B, Wallace J, Rygielski S, Stapleton JT, Martin J, Deeks SG, Landay A. Regulatory B cells inhibit cytotoxic T lymphocyte (CTL) activity and elimination of infected CD4 T cells after in vitro reactivation of HIV latent reservoirs. PLoS One. 2014; 9(4):e92934.
- Stock PG, Barin B, Hatano H, Rogers RL, Roland ME, Lee TH, Busch M, Deeks SG. Reduction of HIV persistence following transplantation in HIV-infected kidney transplant recipients. Am J Transplant. 2014 May; 14(5):1136-41.
- Bashirova AA, Martin-Gayo E, Jones DC, Qi Y, Apps R, Gao X, Burke PS, Taylor CJ, Rogich J, Wolinsky S, Bream JH, Duggal P, Hussain S, Martinson J, Weintrob A, Kirk GD, Fellay J, Buchbinder SP, Goedert JJ, Deeks SG, Pereyra F, Trowsdale J, Lichterfeld M, Telenti A, Walker BD, Allen RL, Carrington M, Yu XG. LILRB2 interaction with HLA class I correlates with control of HIV-1 infection. PLoS Genet. 2014 Mar; 10(3):e1004196.
- Lee SA, Sinclair E, Jain V, Huang Y, Epling L, Van Natta M, Meinert CL, Martin JN, McCune JM, Deeks SG, Lederman MM, Hecht FM, Hunt PW. Low proportions of CD28- CD8+ T cells expressing CD57 can be reversed by early ART initiation and predict mortality in treated HIV infection. J Infect Dis. 2014 Aug 01; 210(3):374-82.http://www.ncbi.nlm.nih.gov/pubmed/21402547
- Byakwaga H, Boum Y, Huang Y, Muzoora C, Kembabazi A, Weiser SD, Bennett J, Cao H, Haberer JE, Deeks SG, Bangsberg DR, McCune JM, Martin JN, Hunt PW. The kynurenine pathway of tryptophan catabolism, CD4+ T-cell recovery, and mortality among HIV-infected Ugandans initiating antiretroviral therapy. J Infect Dis. 2014 Aug 01; 210(3):383-91.
- Lee SA, Sinclair E, Hatano H, Hsue PY, Epling L, Hecht FM, Bangsberg DR, Martin JN, McCune JM, Deeks SG, Hunt PW. Impact of HIV on CD8+ T cell CD57 expression is distinct from that of CMV and aging. PLoS One. 2014; 9(2):e89444.http://www.ncbi.nlm.nih.gov/pubmed/21492857
- Parikh RV, Scherzer R, Nitta EM, Leone A, Hur S, Mistry V, Macgregor JS, Martin JN, Deeks SG, Ganz P, Hsue PY. Increased levels of asymmetric dimethylarginine are associated with pulmonary arterial hypertension in HIV infection. AIDS. 2014 Feb 20; 28(4):511-9.
- Payne RP, Branch S, Kløverpris H, Matthews PC, Koofhethile CK, Strong T, Adland E, Leitman E, Frater J, Ndung'u T, Hunter E, Haubrich R, Mothe B, Edwards A, Riddell L, Chen F, Harrigan PR, Brumme ZL, Mallal S, John M, Jooste JP, Shapiro R, Deeks SG, Walker BD, Brander C, Landis C, Carlson JM, Prado JG, Goulder PJ. Differential escape patterns within the dominant HLA-B*57:03-restricted HIV Gag epitope reflect distinct clade-specific functional constraints. J Virol. 2014 May; 88(9):4668-78.
- Dunham RM, Vujkovic-Cvijin I, Yukl SA, Broadhurst MJ, Loke P, Albright RG, Wong JK, Lederman MM, Somsouk M, Hunt PW, Martin JN, Deeks SG, McCune JM. Discordance between peripheral and colonic markers of inflammation during suppressive ART. J Acquir Immune Defic Syndr. 2014 Feb 01; 65(2):133-41.
- Yukl SA, Sinclair E, Somsouk M, Hunt PW, Epling L, Killian M, Girling V, Li P, Havlir DV, Deeks SG, Wong JK, Hatano H. A comparison of methods for measuring rectal HIV levels suggests that HIV DNA resides in cells other than CD4+ T cells, including myeloid cells. AIDS. 2014 Jan 28; 28(3):439-42.http://www.ncbi.nlm.nih.gov/pubmed/21305005
- Heredia A, Davis C, Amin MN, Le NM, Wainberg MA, Oliveira M, Deeks SG, Wang LX, Redfield RR. Targeting host nucleotide biosynthesis with resveratrol inhibits emtricitabine-resistant HIV-1. AIDS. 2014 Jan 28; 28(3):317-23.
- Michaud HA, de Mulder M, SenGupta D, Deeks SG, Martin JN, Pilcher CD, Hecht FM, Sacha JB, Nixon DF. Trans-activation, post-transcriptional maturation, and induction of antibodies to HERV-K (HML-2) envelope transmembrane protein in HIV-1 infection. Retrovirology. 2014 Jan 28; 11:10.
- Emu B, Moretto WJ, Hoh R, Krone M, Martin JN, Nixon DF, Deeks SG, McCune JM. Composition and function of T cell subpopulations are slow to change despite effective antiretroviral treatment of HIV disease. PLoS One. 2014; 9(1):e85613.
- Boufassa F, Lechenadec J, Meyer L, Costagliola D, Hunt PW, Pereyra F, Deeks S, Pancino G, Taulera O, Lichterfeld M, Delobel P, Saez-Cirion A, Lambotte O, ANRS CO18 HIV Controllers Cohort , Cascade Collaboration in Eurocoord , SCOPE Cohort , International HIV Controllers Study . Blunted response to combination antiretroviral therapy in HIV elite controllers: an international HIV controller collaboration. PLoS One. 2014; 9(1):e85516.
- Hatano H, Bacchetti P, Hsue PY, Deeks SG. Reply to Karch et al. J Infect Dis. 2014 Jul 1; 210(1):159-60.
- Seu L, Ortiz GM, Epling L, Sinclair E, Swainson LA, Bajpai UD, Huang Y, Deeks SG, Hunt PW, Martin JN, McCune JM. Higher CD27+CD8+ T cells percentages during suppressive antiretroviral therapy predict greater subsequent CD4+ T cell recovery in treated HIV infection. PLoS One. 2013; 8(12):e84091.http://www.ncbi.nlm.nih.gov/pubmed/21245154
- Milush JM, López-Vergès S, York VA, Deeks SG, Martin JN, Hecht FM, Lanier LL, Nixon DF. CD56negCD16⁺ NK cells are activated mature NK cells with impaired effector function during HIV-1 infection. Retrovirology. 2013 Dec 18; 10:158.
- Spivak AM, Andrade A, Eisele E, Hoh R, Bacchetti P, Bumpus NN, Emad F, Buckheit R, McCance-Katz EF, Lai J, Kennedy M, Chander G, Siliciano RF, Siliciano JD, Deeks SG. A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy. Clin Infect Dis. 2014 Mar; 58(6):883-90.
- Burbelo PD, Bayat A, Rhodes CS, Hoh R, Martin JN, Fromentin R, Chomont N, Hütter G, Kovacs JA, Deeks SG. HIV antibody characterization as a method to quantify reservoir size during curative interventions. J Infect Dis. 2014 May 15; 209(10):1613-7.